A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia
HIV Infections

About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Sex Behavior, T-Lymphocytes, HIV Antibodies, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Zidovudine, Hemophilia A
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed with caution for Study A: Hepatotoxic drugs. Patients in Study A must have: Hemophilia with no symptoms for AIDS. Most patients will have well-established factor 8 or 9 deficiency. However, patients with other coagulation diseases, such as factor 5 deficiency, and von Willebrand disease, will also be acceptable for the study. Wives in Study B are included even if they are known to be seropositive or are not sexually active at the time the study starts. Prior Medication: Allowed for Study A: Patients who were on the Phase I ZDV study, ACTG 017, or are on ACTG 062 may enter after waiting 3 weeks. Exclusion Criteria Co-existing Condition: Patients in Study A with the following symptoms or conditions are excluded: AIDS-defining illness. Severe ARC. Severe or prolonged toxicity. Concurrent Medication: Excluded for Study A: Isoniazid or rifampin. Treatment for Pneumocystis carinii pneumonia (PCP), oral candidiasis, and localized cutaneous herpes simplex or zoster infections. Probenecid. Aspirin on a regular basis, or for more than 72 hours without contacting the investigator. Drugs causing neutropenia or significant risk of nephrotoxicity. Patients in Study A with the following prior conditions are excluded: AIDS-defining opportunistic infection or malignancy. Unexplained temperature greater than 38 C for more than 5 consecutive days or more than 10 days in any 30-day period in the 2 years prior to entry. Unexplained diarrhea defined as three or more liquid stools per day, persisting more than 7 days within 2 years prior to entry. Unintentional weight loss of greater than 10 lbs. or more than 10 percent of usual body weight within 2 years prior to study entry. Oral hairy leukoplakia at any time prior to entry. Oral candidiasis unrelated to the use of antibiotic therapy for more than 2 weeks within 2 years prior to entry or within the past 3 months. Herpes zoster within 2 years prior to entry into the study. Prior Medication: Excluded for Study A: Antiretroviral agents, including ZDV, ribavirin, HPA-23, rifampin, AL721 within 8 weeks of study entry. Significant course of immunomodulating agents such as steroids (greater than 1 week), isoprinosine, thymic factors within 3 months of study entry. Any other experimental therapy within 3 months of study entry. Discouraged but not forbidden for Study B: Sexual contact with infected husband.
Sites / Locations
- Los Angeles County - USC Med Ctr
- Univ of California / San Diego Treatment Ctr
- Stanford Univ School of Medicine
- Northwestern Univ Med School
- Cook County Hosp
- Chicago Children's Memorial Hosp
- Indiana Univ Hosp
- Tulane Univ School of Medicine
- Children's Hosp of Boston
- Univ of Massachusetts Med Ctr
- Univ of Minnesota
- Cornell Univ Med Ctr
- Mount Sinai Med Ctr
- Univ of Rochester Medical Center
- Univ of North Carolina
- Holmes Hosp / Univ of Cincinnati Med Ctr
- Univ Hosp of Cleveland / Case Western Reserve Univ
- Ohio State Univ Hosp Clinic
- Milton S Hershey Med Ctr
- Hemophilia Ctr of Western PA / Univ of Pittsburgh
- Univ of Pittsburgh Med School
- Baylor College of Medicine
- Univ of Washington